Today: 21 May 2026
AI stocks wobble as AMD slips on forecast and Nvidia faces fresh China questions

AI stocks wobble as AMD slips on forecast and Nvidia faces fresh China questions

NEW YORK, Feb 4, 2026, 06:41 ET — Premarket

Advanced Micro Devices dropped roughly 1.5% to $242.11 in early trading Wednesday, dragging other AI chip stocks down with it amid fresh AI news. Nvidia slid 2.8%, Broadcom tumbled 3.3%, and the iShares Semiconductor ETF slipped around 2%.

After a steep selloff Tuesday, software and cloud stocks took a hit amid concerns that AI might pressure profit margins and shake up established business models. “We’re seeing a lot of software companies across the spectrum get hit,” said Art Hogan, chief market strategist at B. Riley Wealth. Reuters

Nvidia CEO Jensen Huang pushed back against worries on Wednesday, calling the notion that AI will replace software tools “illogical” during a Cisco-hosted AI event in San Francisco. The sell-off in software stocks, partly triggered by a new chatbot update from Anthropic, also hit Asian markets. Reuters

AMD provided a sharper jolt. The firm projects first-quarter revenue around $9.8 billion, with a $300 million margin, falling short of last quarter’s $10.27 billion—even after a late boost from China-bound AI chip sales cleared under a U.S. license. Bernstein analyst Stacy Rasgon remarked that near-term AI figures “are not really inflecting.” Reuters

During a conference call, CEO Lisa Su said demand for AMD’s next-gen AI servers — including shipments to OpenAI and others — is expected to pick up in the second half of the year. She also noted that a global memory-chip shortage won’t limit production. Still, the guidance fell short of expectations in a market geared for what TECHnalysis Research’s Bob O’Donnell called “large blowout quarters.” Reuters

China is also under the microscope for Nvidia investors. The Financial Times reported that sales of its H200 AI chip to China are stalled, awaiting a U.S. national security review. Reuters couldn’t confirm the story right away. Nvidia and the U.S. State Department didn’t respond to Reuters’ requests for comment outside business hours.

OpenAI’s changing chip demands are adding strain to the AI supply chain. Reuters revealed this week that OpenAI has grown frustrated with the speed of certain Nvidia chips used for “inference”—the process of a model responding to user queries—and is exploring other options. Still, Nvidia remains the backbone of most of OpenAI’s inference operations. After the story broke, CEO Sam Altman praised Nvidia, calling them the makers of “the best AI chips in the world.” Reuters

Intel isn’t sitting on the sidelines. CEO Lip-Bu Tan announced plans to develop GPUs for data centers and brought on Qualcomm’s Eric Demmers to spearhead the project. This move clearly targets the space Nvidia has dominated in powering the current AI boom.

The AI trade is growing crowded and pricey, squeezing tolerance for unclear guidance or policy shocks. Those same AI headlines that drive funds into chipmakers can just as quickly trigger outflows once investors question the payoff from all that spending.

The downside is well-known: softer enterprise software demand, sluggish data-center orders, or tighter export controls limiting sales to China. If that scenario unfolds as the market pulls back risk, the entire AI stack could move as a single position.

Investors won’t have long to wait for the next update. Alphabet reports after the closing bell Wednesday, followed by Amazon on Thursday. Attention also turns to ADP’s national employment report at 8:15 a.m. ET, filling the gap left by delayed government data. Direxion’s Jake Behan noted that some traders are pulling back from what’s become a “crowded AI trade.” Reuters

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Take-Two (TTWO) stock eyes a sharp open after forecast raise, GTA VI date held
Previous Story

Take-Two (TTWO) stock eyes a sharp open after forecast raise, GTA VI date held

Intel stock slides after CEO flags new GPU push; investors eye Nvidia’s next readout
Next Story

Intel stock slides after CEO flags new GPU push; investors eye Nvidia’s next readout

Go toTop